MoonLake Immunotherapeutics Class A (MLTX)

The past six months have seen several significant events impacting MoonLake Immunotherapeutics' stock price. In September 2025, the stock experienced a dramatic 90% collapse following the announcement of results from its Phase 3 VELA program. A comeback narrative emerged as additional clinical data became available and management clarified the regulatory pathway. In February 2026, MoonLake announced positive topline results from its Phase 2 clinical trial of sonelokimab in axial spondyloarthritis and reported its 2025 financial results. Earlier in February 2026, MoonLake announced that the FDA granted Fast Track designation for sonelokimab in palmoplantar pustulosis (PPP). In January 2026, the company provided an update on positive feedback from the U.S. FDA regarding the clinical evidence strategy for sonelokimab in HS, confirming that a Biologic License Application (BLA) could be established without additional clinical trials using existing data. Insider selling has also been noted, and a major institutional holder, BVF, trimmed its stake. As of May 6, 2026, the share price was $17.70, representing a decline of 52.93% over the past year.

As a clinical-stage biotechnology company, MoonLake Immunotherapeutics' primary product is still undergoing clinical trials and is not yet commercially available. Therefore, the concept of demand seasonality does not directly apply. The company's demand is more closely tied to investor interest, clinical trial milestones, regulatory approvals, and the potential future market for its therapies.

MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases, operating within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical Products industries. Its primary product in development is Sonelokimab (SLK), a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, being developed to treat various inflammatory conditions, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), palmoplantar pustulosis (PPP), and psoriasis. The company aims to provide next-level therapies to revolutionize outcomes for patients with these serious inflammatory diseases.

MoonLake Immunotherapeutics is headquartered in Zug, Switzerland, and was founded in 2021. The company also maintains offices in the UK and Portugal. While its state of incorporation is the Cayman Islands, its business operations are based out of Switzerland. MoonLake conducts innovative research work and clinical trials globally.

MoonLake Immunotherapeutics' brand reputation experienced a significant setback in September 2025 due to the Phase 3 VELA program results, leading to a 90% stock price drop. However, the company has since worked to rebuild its reputation, with a compelling comeback narrative emerging. Positive Phase 2 results and the FDA Fast Track designation have likely contributed to this recovery in perception.

MoonLake Immunotherapeutics' stock ownership is a mix of institutional, insider, and public/individual investors. Major institutional owners include BVF Inc/il, Deep Track Capital, Cormorant Asset Management, LP, and others. Bihua Chen is identified as the largest individual shareholder, owning 6.75% of the company's shares. Approximately 78.57% of the stock is held by institutional shareholders, 22.80% by insiders, and a smaller percentage by retail investors.